Charles River Laboratories (CRL) Tops Q2 EPS by 5c, beats revenue, offers guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $282.00 +1.81%
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
WPRT, ITRG, ALM, More
Financial Fact:
Continuing operations (in dollars per share): 0.79
Today's EPS Names:
WPRT, ITRG, ALM, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.69, $0.05 better than the analyst estimate of $2.64. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $10.30-$10.90.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charles River Labs (CRL) PT Raised to $300 at TD Cowen
- Aardvark Therapeutics (AARD) Tops Q2 EPS by 21c
- Transact Technologies (TACT) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
